Advancing alcohol-related liver disease: from novel biomarkers to refining selection for liver transplantation
Ayares, G. et al. Public health measures and prevention of alcohol-associated liver disease. J. Clin. Exp. Hepatol. 12, 1480–1491 (2022).
Griswold, M. G. et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 392, 1015–1035 (2018).
Kwong, A. J. et al. OPTN/SRTR 2020 Annual Data Report: Liver. Am. J. Transplant 22 (Suppl. 2), 204–309 (2022).
Arab, J. P. et al. Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study. J. Hepatol. 75, 1026–1033 (2021).
Niu, L. et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat. Med. 28, 1277–1287 (2022).
Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505–511 (2019).
Duan, Y. et al. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. Nat. Commun. 12, 7172 (2021).
Mathurin, P. et al. Early liver transplantation for severe alcoholic hepatitis. N. Engl. J. Med. 365, 1790–1800 (2011).
Louvet, A. et al. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study. Lancet Gastroenterol. Hepatol. 7, 416–425 (2022).